Accepting applications until August 1
Accepting applications until August 1
Chunhuan Lao, Mohana Mondal, Marion Kuper-Hommel, et al. Asia Pac J Clin Oncol. 2023 Aug;19(4):482-492
This study aims to identify the factors that affect the public healthcare costs of stage I-III breast cancer and stage IV cancer in New Zealand. We identified 16,977 stage I-III and 1,093 stage IV breast cancer patients eligible f... Read More
Li Sun, Rosa Legood, Isabel Dos-Santos-Silva, et al. PLoS One. 2018 Nov 26;13(11):e0207993
This study aimed to conduct a systematic review to compare treatment costs of breast cancer by stage at diagnosis across countries at different levels of socio-economic development, and to identify key methodological differences i... Read More
Amye J Tevaarwerk, Kris Kwekkeboom, Kevin A Buhr, et al. Cancer. 2021 Mar 1;127(5):801-808
Post cancer work limitations may affect a substantial proportion of patients and contribute to the "financial toxicity" of cancer treatment. The degree and nature of work limitations and employment outcomes are poorly understood f... Read More
Roy A Nielsen, Eliva Atieno Ambugo, Steffen Torp, et al. J Public Health Res. 2026 Jan 26;15(1):22799036251410249
Breast cancer and its treatment may contribute to an increased risk of unemployment, influenced by both disease-related factors and socioeconomic determinant. This retrospective study investigated long-term employment among breast... Read More
Goran Bencina, Nour Chami, Robert Hughes, et al. J Med Econ. 2023 Jan-Dec;26(1):254-261
Breast cancer (BC) poses a public health challenge as the most commonly diagnosed cancer among women globally. While BC mortality has declined across Europe in the past three decades, an opposite trend has been reported in some tr... Read More
Agnes Brandtmüller, Anne Meiwald, Edward Oliver, et al. J Cancer Policy. 2024 Dec:42:100499
Cancer caused an estimated 2.2 million deaths across Europe in 2020. This analysis estimated the cost of lost productivity due to premature deaths associated with lung, breast and melanoma cancer and investigated the temporal tren... Read More
Ghazaleh Pourali, Minglu Liu, Supriya S Sherpa, et al. Breast Cancer Res. 2025 Jul 1;27(1):118
Given the rising incidence of breast cancer, especially in premenopausal women, there is an urgent need to identify additional risk-reducing medications to accelerate prevention, as only a few are currently approved. Out of 8,598... Read More
Edoardo Botteri, Paula Berstad, Sven Sandin, Elisabete Weiderpass. Acta Oncol. 2021 Jul;60(7):827-834
We investigated this issue in the Swedish Women's Lifestyle and Health Cohort Study. We included 29,930 women. From 1991/92 to 2003, median age changed from 40.0 to 51.7 years, alcohol consumption from 2.5 to 4.7 grams/day, BMI fr... Read More
Pasquale Marino, Mariangela Mininni, Giovanni Deiana, et al. Nutrients. 2024 Mar 11;16(6):800
Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence has increased over the years. A potential strategy to counter the growing spread of various forms of cancer is the adoption... Read More
Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, et al. Lancet Oncol. 2025 Jan;26(1):27-36
We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast can... Read More
Peter Schmid, Javier Cortes, Rebecca Dent, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-con... Read More
Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al. Nat Med. 2025 Feb;31(2):442-448
We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2-grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned... Read More